赛托生物(300583.SZ)：甲泼尼龙化学原料药上市申请获批准

Group 1 - The core point of the article is that Saito Bio (300583.SZ) announced that its subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of Methylprednisolone [1] - Methylprednisolone is a medium-acting, non-halogenated corticosteroid used for emergency treatment in critical illnesses and is applicable for various conditions including endocrine disorders, rheumatic diseases, collagen diseases, skin diseases, allergic reactions, ophthalmic diseases, gastrointestinal diseases, blood diseases, leukemia, shock, cerebral edema, multiple neuritis, myelitis, and to prevent vomiting caused by cancer chemotherapy [1]